| Methods |
2‐week single‐blind placebo run‐in; inclusion criteria= supine DBP 95‐115 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
All patients: n=40(19 males,21 females); mean age=58 years; baseline upright SBP=154(15) mm Hg, DBP=102(7) mm Hg |
| Interventions |
Perindopril 4 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough erect SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SEM of change reported, endpoint BP and SD not reported; calculated SD of change from N and SEM of change; BP data from Table 2, p. 329; Jadad score=4; funding source= Servier |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
